Chang Han

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Matthew D. Hellmann, Margaret K. Callahan, Mark M. Awad et al. · Cancer Cell · 2018 · 894 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Neal Ready, Matthew D. Hellmann, Mark M. Awad et al. · Journal of Clinical Oncology · 2019 · 596 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Daniel K. Wells, Marit M. van Buuren, Kristen K. Dang et al. · Cell · 2020 · 536 citations · Full text

Life Sciences, Immunology, Oncology +16